The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/appi.ps.54.5.665

Introduction by the column editor: The problem of noncompliance is one that affects all areas of medicine. Some opinion holds that it may be worse for psychiatric disorders, particularly the psychoses, and that the side effects of the older or conventional antipsychotics have played a major role in poor compliance. Side effects have also been proposed as the reason long-acting medications have been unpopular in the United States. This explanation, like many others, seems a bit simplistic and would not explain why European countries and Australia use ten times as many long-acting drugs as the United States.The arrival of atypical antipsychotics, with their lower rate of extrapyramidal effects, was greeted positively as an advance on the older drugs. It was suggested that the lower rate of side effects would improve compliance. However, few data to support this suggestion have been reported.